LCNDG Rapid Review: Bendamustine for relapsed follicular lymphoma refractory to rituximab

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for a NICE single technology appraisal (STA) in May 2010. In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify comparative clinical evidence suitable for a NICE appraisal in people with rituximab refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance. NICE therefore terminated this single technology appraisal. The manufacturer plan to make a resubmission to NICE when data from a comparative trial is available but there is no date as to when this will be.   The best available evidence to support bendamustine for this indication comes from two phase II non comparative trials. Both trials assessed bendamustine in patients with indolent B-cell lymphoma, of which follicular lymphoma made up the ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news